DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.
03/16/2018 - 9:30 pm | Corporate | Finance
DBV Technologies Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-FDownload PDF (319 KB)
03/14/2018 - 2:30 am | Finance
DBV Technologies Reports Full Year 2017 Financial ResultsDownload PDF (398 KB)
03/07/2018 - 1:30 am | Conferences
DBV Technologies to Present at the Barclays Global Healthcare ConferenceDownload PDF (314 KB)